Vaughan David Investments LLC IL Purchases New Holdings in ResMed Inc. (NYSE:RMD)

Vaughan David Investments LLC IL purchased a new stake in shares of ResMed Inc. (NYSE:RMDFree Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 170,459 shares of the medical equipment provider’s stock, valued at approximately $29,322,000. Vaughan David Investments LLC IL owned about 0.12% of ResMed as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of RMD. Cambridge Investment Research Advisors Inc. boosted its position in ResMed by 15.7% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 3,050 shares of the medical equipment provider’s stock valued at $740,000 after purchasing an additional 414 shares during the last quarter. Cibc World Market Inc. boosted its position in ResMed by 13.0% during the first quarter. Cibc World Market Inc. now owns 1,000 shares of the medical equipment provider’s stock valued at $243,000 after purchasing an additional 115 shares during the last quarter. Vontobel Holding Ltd. boosted its position in ResMed by 14.5% during the first quarter. Vontobel Holding Ltd. now owns 8,112 shares of the medical equipment provider’s stock valued at $2,020,000 after purchasing an additional 1,025 shares during the last quarter. Sei Investments Co. boosted its position in ResMed by 7.8% during the first quarter. Sei Investments Co. now owns 40,740 shares of the medical equipment provider’s stock valued at $9,781,000 after purchasing an additional 2,955 shares during the last quarter. Finally, Prudential PLC acquired a new stake in shares of ResMed in the first quarter valued at approximately $694,000. 54.98% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other ResMed news, General Counsel Michael J. Rider sold 200 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $173.25, for a total transaction of $34,650.00. Following the transaction, the general counsel now owns 6,688 shares in the company, valued at approximately $1,158,696. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, General Counsel Michael J. Rider sold 200 shares of ResMed stock in a transaction on Friday, March 1st. The stock was sold at an average price of $173.25, for a total value of $34,650.00. Following the transaction, the general counsel now owns 6,688 shares in the company, valued at approximately $1,158,696. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Peter C. Farrell sold 10,935 shares of ResMed stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $182.66, for a total value of $1,997,387.10. Following the completion of the transaction, the director now owns 157,404 shares in the company, valued at approximately $28,751,414.64. The disclosure for this sale can be found here. Insiders have sold a total of 11,216 shares of company stock worth $2,046,617 in the last 90 days. Company insiders own 1.21% of the company’s stock.

ResMed Price Performance

ResMed stock traded down $3.65 during mid-day trading on Friday, reaching $185.86. 657,149 shares of the company were exchanged, compared to its average volume of 983,021. The company has a fifty day simple moving average of $187.01 and a 200-day simple moving average of $168.98. ResMed Inc. has a 12 month low of $132.24 and a 12 month high of $243.52. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.11 and a quick ratio of 1.89. The firm has a market cap of $27.34 billion, a PE ratio of 31.32, a PEG ratio of 2.40 and a beta of 0.67.

ResMed (NYSE:RMDGet Free Report) last posted its quarterly earnings data on Wednesday, January 24th. The medical equipment provider reported $1.88 EPS for the quarter, topping analysts’ consensus estimates of $1.81 by $0.07. ResMed had a return on equity of 23.86% and a net margin of 19.77%. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.15 billion. During the same quarter last year, the company earned $1.66 EPS. The company’s revenue was up 12.5% on a year-over-year basis. As a group, equities research analysts expect that ResMed Inc. will post 7.45 earnings per share for the current fiscal year.

ResMed Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 14th. Shareholders of record on Thursday, February 8th were paid a dividend of $0.48 per share. The ex-dividend date of this dividend was Wednesday, February 7th. This represents a $1.92 dividend on an annualized basis and a yield of 1.03%. ResMed’s dividend payout ratio (DPR) is presently 31.74%.

Analyst Ratings Changes

A number of research firms have recently issued reports on RMD. KeyCorp began coverage on ResMed in a research report on Tuesday, February 6th. They issued an “overweight” rating and a $227.00 price objective for the company. Needham & Company LLC raised their price objective on ResMed from $215.00 to $224.00 and gave the company a “buy” rating in a research report on Monday, April 1st. UBS Group raised their price objective on ResMed from $175.00 to $180.00 and gave the company a “neutral” rating in a research report on Thursday, January 25th. Royal Bank of Canada raised their price objective on ResMed from $181.00 to $182.00 and gave the company a “sector perform” rating in a research report on Thursday, January 25th. Finally, Oppenheimer raised their price objective on ResMed from $185.00 to $205.00 and gave the company an “outperform” rating in a research report on Tuesday, January 30th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, ResMed has a consensus rating of “Moderate Buy” and an average target price of $199.20.

Check Out Our Latest Stock Analysis on ResMed

About ResMed

(Free Report)

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Recommended Stories

Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMDFree Report).

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.